SLC26A4 and cardiac hypertrophy: Consistent with RT-qPCR results, immunohistochemistry results showed that siRNA-SLC26A4 significantly attenuated the expression levels of ANP and BNP in PE-induced cardiac hypertrophy models (Figs. 8A–8L).